Astraveus Enhances Leadership with New Strategic Appointments
Astraveus SAS, a pioneer in the development of cell therapies, is taking significant steps to fortify its leadership team and Board of Directors. This move comes as the company gears up for the launch of its groundbreaking Lakhesys Benchtop Cell Factory™. Notable appointments include Jean-Paul Mangeolle as Chairman of the Board, David Newble as an Independent Board Member, and Laurence Riot Lamotte as Chief Financial Officer.
New Leadership Insight
Jean-Paul Mangeolle brings over three and a half decades of invaluable experience in the life sciences sector. His extensive background includes holding key executive roles at high-profile companies like Millipore (now MilliporeSigma) and Danaher. This wealth of experience positions him to effectively lead and guide Astraveus through its next phase of growth.
David Newble is another significant addition to the team, recognized for his leadership roles across various life science organizations. Previously, he was the CEO of notable firms such as SPT Labtech and TAP Biosystems. His insights into protein analytics and bioprocessing will be crucial as Astraveus advances its innovative production techniques.
Financial Leadership
Laurence Riot Lamotte, serving as CFO, boasts over 30 years in finance, with more than 20 years dedicated to financial leadership within the life sciences arena. Before joining Astraveus, she successfully led financial strategies at Evexta Bio, solidifying her expertise in navigating complex financial landscapes.
Strategic Direction and Vision
Jérémie Laurent, Chief Executive Officer of Astraveus, expressed confidence in the newly appointed leaders, stating that their combined expertise will significantly boost the company's operations and accelerate its development. "This is a transformational time for Astraveus, and we are confident that our team is better placed than ever to advance our Lakhesys Benchtop Cell Factory™," he shared enthusiastically.
Meanwhile, Jean-Paul Mangeolle, in his new role as Chairman, emphasized his excitement about Astraveus's innovative technologies. He noted, "The microfluidic technology being developed here can translate to improved process optimization and scalability throughout the entire manufacturing process. I look forward to leveraging my experience to help guide the successful commercialization of the Lakhesys™ portfolio."
Innovation at the Forefront
David Newble echoed similar sentiments, highlighting his privileged position in supporting Astraveus as an advisor over the past year. He believes that the Lakhesys Benchtop Cell Factory™ is uniquely poised to elevate the cell therapy industry, fostering its maturity and growth.
Additionally, Laurence Riot Lamotte acknowledged the critical need for innovative bioprocessing solutions within the realm of cell therapies. She is keen on contributing to Astraveus's promising roadmap and enhancing the accessibility of these groundbreaking treatments.
The Lakhesys Benchtop Cell Factory™
Astraveus is making impressive strides towards the launch of its innovative Lakhesys Benchtop Cell Factory™. Recently, the company achieved a notable milestone by demonstrating the first end-to-end production of CAR-T cells within a microfluidic system, showcasing its unique approach that not only streamlines manufacturing processes but also reduces costs and boosts efficiency.
About Astraveus
Astraveus is a life science company based in Paris, dedicated to transforming the landscape of cell therapies. With the Lakhesys Benchtop Cell Factory™, the goal is to deliver high-quality bioprocessing solutions at a fraction of traditional costs. By adopting advanced microfluidic technology, Astraveus aims to optimize cellular processes from pre-clinical stages through to commercial-scale manufacturing.
Founded in 2016 by Jérémie Laurent in Paris, a hub for cutting-edge cell therapy research, Astraveus is committed to revolutionizing the development and production of cell-based therapies. The vision is to make these life-changing treatments accessible to individuals in need, contributing to a healthier future for all.
About Jean-Paul Mangeolle
Jean-Paul Mangeolle has an extensive career as a life science executive, having previously served as President of the SCIEX Group and held executive roles at Merck KGaA, overseeing the Process Solutions division. His board experience spans various established and emerging life science companies, where he has driven growth and innovation.
About David Newble
David Newble's impressive trajectory in the life sciences includes leadership positions at SPT Labtech and TAP Biosystems, where he contributed to the development of the acclaimed Ambr® bioreactor system. Furthermore, he founded Fluidic Sciences, a leading protein analytics firm, reinforcing his reputation in the sector.
About Laurence Riot Lamotte
With a rich background in financial leadership, Laurence Riot Lamotte comes to Astraveus from Evexta Bio. Her experience includes pivotal roles at IntegraGen, where she spearheaded several significant financing operations, including the company's IPO, showcasing her expertise in navigating complex financial environments that support growth in the biotech industry.
Frequently Asked Questions
What is the purpose of the new appointments at Astraveus?
The new appointments aim to strengthen Astraveus's leadership team to support its growth and innovation goals, particularly with the upcoming launch of the Lakhesys Benchtop Cell Factory™.
Who is Jean-Paul Mangeolle?
Jean-Paul Mangeolle is the new Chairman of the Board at Astraveus, bringing over 35 years of experience in the life sciences sector.
What role does Laurence Riot Lamotte hold?
Laurence Riot Lamotte has been appointed as the Chief Financial Officer of Astraveus.
How does the Lakhesys Benchtop Cell Factory™ aim to impact the industry?
The Lakhesys Benchtop Cell Factory™ seeks to reduce manufacturing costs and improve efficiency within the cell therapy sector, thereby accelerating advancements in this vital area of healthcare.
When was Astraveus founded?
Astraveus was founded in 2016 at the Saint-Louis Hospital in Paris, focusing on breakthroughs in cell therapy research.
